Banana and mosquito research
13 August, 2005Two researchers from Queensland are contributing to a $436 million global plan to improve the health of millions of people in some of the world's poorest countries.
Marine research may benefit cancer patients
04 July, 2005A team of international scientists – including Australians – has made a breakthrough in solving the problem that had put the development of marine-derived pharmaceuticals on hold for years.
Solvent recovery unit
20 June, 2005 | Supplied by: http://www.novasys.com.au/Ofru Recycling has introduced a solvent recovery system with the ASC-150 that meets the ATEX European safety standard and contains an integrated steam heating system, rather than the conventional thermal oil heating system.
Researchers get first peek at amyloid's spine
09 June, 2005Researchers at the Howard Hughes Medical Institute in US have provided the first detailed look at the core structure of the abnormal protein filaments found in at least 20 devastating diseases, ranging from Alzheimer's to Creutzfeldt-Jakob disease, the human version of “mad cow†disease.
CSIRO robots team up with MIT
01 June, 2005Australian robotics research has received some fresh input as a new partnership between the CSIRO and the MIT computer science and artificial intelligence laboratory in USA has been formed.
Dye to pinpoint diseases
23 May, 2005University of Toronto researchers have designed a chemical screening tool that will light up when dangerous pathogens and diseases in air, water and bodily fluids are present.
Marine invader under monitoring
18 May, 2005Scientists have developed a genetic tool to help environmental authorities monitor the spread and impact of Australia's most invasive marine species, the New Zealand screwshell.
Mouse models
13 May, 2005 | Supplied by: http://www.artisoptimus.com/ArtisOptimus and Taconic Farms are jointly using their strengths in MEF production and patented mouse models to bring a collection of primary mouse embryonic fi-broblasts to the research com-munity, under the brand name OptiMEF.
Animal-friendly herbicide in development
13 May, 2005Scientists at Monash University are researching an environmentally friendly alternative to herbicides that targets weeds but does not affect animals. This research could also lead to new treatments for the internationally alarming health issue of tuberculosis infection.
Screening drugs of abuse by LC/MS
08 May, 2005 | Supplied by: Keysight Technologies Australia Pty LtdHigh throughput screening of drugs of abuse is performed at St Olav Hospital by LC/MS. Typically done by immunoassay, this overview describes the procedures for using this highly selective and quantitative LC/MS methodology
Non-viral vectors deliver genes
05 May, 2005A gene therapy method that doesn't rely on potentially toxic viruses as vectors may be growing closer as the result of in vitro research results reported by University at Buffalo scientists in the current online issue of the Proceedings of the National Academy of Sciences.
Research aids coughing
13 April, 2005UTS Professor Ashley Craig is involved in a project in the NSW Premier's spinal chord injury (SCI) research program to develop an electrical stimulus to help quadriplegics cough.
Keeping frog disease under control
11 April, 2005A workshop on new methods of detecting and controlling the spread of one of the world's most deadly frog diseases – chytridiomycosis – was recently held at CSIRO Livestock Industries' Australian Animal Health Laboratory (AAHL) in Geelong, Victoria.
Gene revolution in India
28 February, 2005It’s the news they have all been waiting for. After years of living under the threat of another devastating epidemic of downy mildew, a disease similar to that which caused the Irish potato famine, India’s poorest farmers have been offered a lifeline in the form of a new disease-resistant hybrid. The hybrid has been produced in record time using modern biotechnology techniques.
Cell processing facility contracted for clinical trials
16 February, 2005Australia’s adult stem cell company, Mesoblast has signed an agreement for production of specialised adult stem cells, known as Mesenchymal Precursor Cells (MPCs), to be used in human pilot clinical trials in patients with orthopaedic and cardiovascular diseases.
